Latest News

Final Results

Final Results

Quantum Pharma Plc (AIM: QP.), the growing, service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, today announces its final results for the year ended 31 January 2016.

Highlights

 

2016

2015

Movement

Revenue

£70.0 million

£61.7 million

+13%

Adjusted EBITDA

£12.7 million

£12.2 million

+4%

Operating profit

£7.0 million

£6.7 million

+5%

Adjusted profit before tax

£10.0 million

£5.7 million

+75%

Basic EPS1

4.5 pence

1.3 pence

+246%

Development expenditure

£6.4 million

£3.1 million

+106%

Net debt

£24.6 million

£9.0 million

+£15.6 million

 

1 The 2016 EPS has basic weighted average number of shares of 125.0 million (2015: 54.5 million) due to the timing of the AIM flotation.

  • Record year for the Group
  • New banking facilities in place with RBS and Lloyds which position the Group well for the future
  • Final dividend of 1.0 pence per ordinary share, subject to approval at the AGM, bringing the total dividend for the financial year to 1.5 pence per ordinary share

Operational Highlights

  • Acquisitions of Lamda and NuPharm, significantly enhancing the Group’s product pipeline, development capabilities and manufacturing infrastructure
  • Investment in key senior management team appointments including the appointment of a Managing Director of the Niche Pharmaceuticals division
  • Product pipeline significantly increased in size and value
  • Successful launch of first two products in the Mucodis® range
  • Out-licence of Aviticol® 20 000IU capsules to a major German pharmaceutical company for€1.5million
  • Significant tender and contract wins in homecare and strong progress made with the development of Biodose Connect™

Post year end:

  • Review of the Niche Pharmaceuticals division and subsequent programme of actions largely completed
  • Product pipeline progressed:
    • launch of ergocalciferol 50 000IU vitamin D capsules;
    • UK marketing authorisation for 800IU and 1000IU vitamin D capsules;
    • over 20 products submitted to regulatory authorities; and
    • over 40 products in pre-registration development or assessment and others being added.
  • New agreements signed with:
    • AAH Pharmaceuticals Limited, the UK’s leading pharmaceutical wholesaler;
    • Moorfields Pharmaceuticals; and
    • a large pharmaceutical company to compound and distribute a cancer treatment.
  • Appointment of Chris Rigg as Chief Financial Officer.

Andrew Scaife, Chief Executive Officer of Quantum Pharma, commented:  “During the past year, we have made progress in developing several key aspects of Quantum Pharma’s business, to put in place a strong platform from which the Group can deliver its strategy.  We have improved the Group’s infrastructure and management, and reviewed and significantly improved our processes around monitoring and delivery of the product pipeline, in addition to receiving external validation of its potential value.  I am excited about the potential of the product pipeline and am pleased that, since the year end, we have received marketing authorisations or approvals to launch three new licensed products with five product lines into the UK market.

“Although it is early in the year, trading performance in the first quarter of the current financial year has been strong.  As the product pipeline converts our financial performance for the current financial year remains second half weighted.  The pipeline of products due to launch this financial year are currently on track, and as such we are confident in the outlook for the year.”

A copy of the final results presentation given by Andrew Scaife (Chief Executive Officer) and Chris Rigg (Chief Financial Officer) will be released on Tuesday, 10 May 2016 at http://ir.quantumpharmagroup.com/content/investor/presentations.asp

 

Posted by: Quantum Webmaster on 10th May 2016